1. Introduction {#sec1}
===============

UC is a chronic inflammatory condition of the intestinum crassum whose etiology remains unknown. Cytokines are crucial components of the inflammatory pathways that take place during the active and chronic phases of UC.

NF-*κ*B is a key regulator of inducible expression of many genes that are involved in immune and inflammatory responses in the intestinal tract \[[@B1]\]. NF-*κ*B can activate anti-apoptotic genes and repress the apoptosis of some inflammatory cells, thereby elongating and worsening tissue inflammatory injury \[[@B2]\]. TNF-*α* is an important proinflammatory cytokine which is involved in systemic inflammation, and stimulates acute phase reactions \[[@B3]\]. Alterations in the regulation of TNF-*α*, especially TNF-*α* overexpression, have been implicated in a variety of symptoms associated with UC. Inflammation, anorexia, and weight loss are all associated with increased levels of TNF-*α* expression \[[@B4]\].

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of transcription factors. The antidiabetic drugs thiazolidinediones (TZDs) are ligands for the *γ* subtype of PPARs. High levels of PPAR*γ* protein are expressed by the colonic epithelium. Recent evidence suggests a possible anti-inflammatory effect of PPAR*γ* ligands, including TZDs, particularly in the colon \[[@B5]\]. Treatment with PPAR*γ* ligands has been demonstrated to attenuate inflammatory cytokine production, inflammatory cell proliferation \[[@B6]\].

We conducted rats model of UC induced by the mixture solution of 2,4,6-trinitrobenzenesulfonic acid solution (TNBS) and ethanol through enema, and after these rats were treated with rosiglitazone, a kind of TZDs, by gastric lavage, the colonic mucosal expression of PPAR*γ*, NF-*κ*B, and TNF-*α* were detected to demonstrate the protective role of rosiglitazone to rats with UC.

2. Methods {#sec2}
==========

2.1. Materials {#sec2.1}
--------------

Healthy male SD rats weighing 180--220 g and aged 4--8 weeks were supplied by the SPF laboratory animal center of Dalian Medical University. TNBS was purchased from Sigma. Rosiglitazone maleate tablets were supplied by GlaxoSmithKline. PPAR*γ*, NF-*κ*B, and TNF-*α* polyclonal antibodies were supplied by Bioworld Technology. The MaxVision TM plus Poly HRP (Mouse/Rabbit) IHC Kit was supplied by Beijing Zhongshan Goldenbridge Biotechnology Co., Ltd. Primers, DNA markers (DL 2000), Takara RNA polymerase chain reaction (PCR) kit3.0 (AMV) kit were from Dalian, Takara Co. Ltd.

2.2. Animal Treatment {#sec2.2}
---------------------

A total of 72 SD rats were randomly divided into three groups: a control group, a rosiglitazone treatment group, and a UC model group, each group had 24 rats. The SD rat model of UC was established by administering the mixture solution of TNBS (100 mg/kg) and 50% ethanol (0.25 mL) by enema. The control group was subject to enema and gastric lavage with normal saline. For the rosiglitazone treatment group, TNBS was administered by enema and rosiglitazone was administered by gastric lavage (8 mg/kg once a day). The UC model group was subjected to TNBS enema and the gastric lavage was saline control. Rats from all groups were sacrificed on days 7, 14, 21, and 35, 6 rats per group were sacrificed each day after the enema and colonic tissue, 2.0--10.0 cm from the anus, was collected for HE staining, RT-PCR and immunohistochemistry analysis. Rats were kept in a normally controlled breeding room with standard laboratory food and water for one week before the experiments. The rats were maintained in accordance with internationally accepted principles for laboratory animal use.

2.3. Disease Activity Index (DAI) and Colonic Mucosa Damage Index (CMDI) Scoring {#sec2.3}
--------------------------------------------------------------------------------

The rats were weighed and checked for behavior, stool consistency, and the presence of gross blood in the stool every day. The scores were assigned as follows: percentage of body weight reduction (0, no change; 1, 1--5%; 2, 6--10%; 3, 11--15%; 4, \>15%); stool consistency (0, normal; 2, loose; 4, diarrhea); and the presence of fecal blood (0, normal; 2, positive occult blood test; 4, visible bleeding) \[[@B7]\]. The DAI was calculated as the sum of these scores.

Rats were sacrificed at the timepoints indicated and the entire colon was excised from the cecum to the anus and opened longitudinally. Macroscopic damage was evaluated using a validated (CMDI) scoring system with slight modifications \[[@B8]\]. The numerical rating score was as follows: 0, no inflammation; 1, local hyperemia and edema without ulcers or erosions on mucosal surface; 2, ulceration without hyperemia; 3, ulceration and adhesions at one site; 4, two or more sites of inflammation and ulceration extending \>1 cm; 5, ulceration extending more than 2 cm.

2.4. Pathological Observation {#sec2.4}
-----------------------------

Paraffin-embedded and formalin-fixed colon samples were cut into 4-*μ*m thick sections for HE staining and pathological observation.

2.5. PPAR*γ*, NF-*κ*B, and TNF-*α* mRNA Expression {#sec2.5}
--------------------------------------------------

mRNA was extracted from colonic tissue samples using Trizol according to the manufacturer\'s protocols (Invitrogen) and reverse transcription polymerase chain reaction (RT-PCR) was done according to the instructions of the Takara RNA PCR kit3.0 (AMV). An equal amount of cDNA from each sample was amplified using primers specific to each gene ([Table 1](#tab1){ref-type="table"}). DNA amplification was done using a thermocycler under the following conditions: for PPAR*γ*, 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 60 s, and extension at 72°C for 60 s; for NF-*κ*B p65, 35 cycles of denaturation at 94°C for 30 s, annealing at 59°C for 30 s, and extension at 72°C for 60 s; for TNF-*α*, 35 cycles of denaturation at 94°C for 45 s, annealing at 54°C for 30 s, and extension at 72°C for 60 s; for *β*-actin, 35 cycles of denaturation at 94°C for 30 s, annealing at 62°C for 30 s, and extension at 72°C for 60 s. RT-PCR products were measured by photodensitometry using a gel image analysis system after agarose gel electrophoresis and ethidium bromide staining.

2.6. Measurement of PPAR*γ*, NF-*κ*B, and TNF-*α* Protein Expression {#sec2.6}
--------------------------------------------------------------------

Immunohistochemistry was done according to the Max Vision kit protocol. Image analysis software (Image-pro plus 6.0) was used to measure the light density of positive control cells in which the cytoplasm was tan-yellow or brown after 3,3\'-diaminobenzidine (DAB) staining. For each section, the positive integrated optical density (IOD) and total area of five representative visual fields without overlap were observed under high-power microscope (×400). The ratio of IOD and total area represents the mean value of optical density, with a higher ratio indicating a higher level of protein expression.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Data showed a normal distribution and are expressed as means ± standard deviation. The responses of different experimental groups were analyzed using one-way ANOVA. Spearman correlation analysis was used to study the relationship between PPAR*γ*, NF-*κ*B, and TNF-*α*. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 19.0 for windows.

3. Results {#sec3}
==========

3.1. Results of DAI and CMDI {#sec3.1}
----------------------------

The DAI and CMDI of the UC model group were significantly higher than that of the control group (*P* \< 0.05) at all timepoints. The DAI and CMDI of the rosiglitazone treatment group were reduced significantly on days 14, 21, and 35 than that of the UC model group (*P* \< 0.05; [Table 2](#tab2){ref-type="table"}).

3.2. Pathological Change under Light Microscope (HE Staining) {#sec3.2}
-------------------------------------------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, the colonic mucosa structure was intact in the control group. Mucosa and submucosa defects could be seen with infiltrations of inflammatory neutrophils and lymphocytes in the lamina propria of the model group on day 14. The degree of mucosal inflammation relieved in the rosiglitazone treatment group on day 14. Regenerated epithelia covered the surface of ulcer and the mucosa tended to be complete. The base of ulcer was filled with tissues and scars.

3.3. Results of RT-PCR {#sec3.3}
----------------------

In the control group, expression of PPAR*γ* mRNA in the colonic mucosa was significantly higher compared to the UC model group (*P* \< 0.05), but the NF-*κ*B and TNF-*α* expression was significantly less (*P* \< 0.05). In the rosiglitazone treatment group, PPAR*γ* mRNA expression increased significantly than that of the model group on days 7, 14, 21, and 35 (*P* \< 0.05), but the NF-*κ*B and TNF-*α* expression reduced significantly (*P* \< 0.05) ([Table 3](#tab3){ref-type="table"}).

3.4. Results of Immunohistochemistry {#sec3.4}
------------------------------------

In the control group, expression of PPAR*γ* protein in the colonic mucosa was significantly higher compared to the UC model group (*P* \< 0.05), but the NF-*κ*B and TNF-*α* expression was significantly less (*P* \< 0.05). In the rosiglitazone treatment group, PPAR*γ* protein expression increased significantly than that of the model group on days 7, 14, 21, and 35 (*P* \< 0.05), but the NF-*κ*B and TNF-*α* expression reduced significantly (*P* \< 0.05) ([Table 4](#tab4){ref-type="table"}; Figures [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

3.5. Correlation of PPAR*γ*, NF-*κ*B, and TNF-*α* Protein Expression in Rosiglitazone Treatment Group {#sec3.5}
-----------------------------------------------------------------------------------------------------

Correlation studies showed that the expression of PPAR*γ* protein was significantly negatively correlated with that of NF-*κ*B protein. The correlating factor was −0.881 (*P* \< 0.05).

The NF-*κ*B protein expression was significantly positively correlated with that of TNF-*α*. The correlating factor was 0.943 (*P* \< 0.05).

4. Discussion {#sec4}
=============

UC is a chronic inflammatory condition of the intestinum crassum that etiology remains unknown. Cytokines are crucial components of the inflammatory pathways that take place during the active and chronic phases of UC. UC likely results from deregulation of colonic mucosal immunity and breakdown of delicate balance of proinflammatory and anti-inflammatory cytokines.

NF-*κ*B is a key regulator of inducible expression of many genes that are involved in immune and inflammatory responses in the intestinal tract. NF-*κ*B can activate anti-apoptotic genes and repress the apoptosis of some inflammatory cells, thereby elongating and worsening tissue inflammatory injury \[[@B2]\]. TNF-*α* is an important proinflammatory cytokine which is involved in systemic inflammation and stimulates acute phase reactions. Alterations in the regulation of TNF-*α* have been implicated in a variety of symptoms associated with UC. Inflammation, anorexia, and weight loss are all associated with increased levels of TNF-*α* expression \[[@B4]\]. Our result also showed that the colonic mucosal expression of NF-*κ*B and TNF-*α* was significantly higher in the UC model group than control group. We confirmed that the two factors are involved in the production of colonic mucosal inflammation and ulceration in the pathogenesis of UC.

PPAR*γ* is predominantly detected in adipose tissue, intestine, and macrophages. A growing body of evidence suggests that PPAR*γ* play a role in inhibiting inflammation. Impaired expression of PPAR*γ* in colonic epithelial cells in UC and increased expression in hypertrophic mesenteric adipose tissue in Crohn\'s disease (CD) have been reported \[[@B9]\]. Decreased gene expression of PPAR*γ* was found from rectal biopsies in patients with active UC and its expression was negatively correlated with the severity of endoscopic disease activity \[[@B10]\].

Our results demonstrated that the colonic mucosal expression of PPAR*γ* in the control group was significantly higher compared to the UC model group, either on the mRNA level or protein level. The evidence suggests that PPAR*γ* plays an important protective role in the process of UC. The molecular mechanisms by which PPAR*γ* regulates inflammatory response are not fully understood. PPAR*γ* has been proposed as a key inhibitor of colitis through attenuation of NF-*κ*B activity \[[@B9]\]. Ricote et al. demonstrated that PPAR*γ* inhibits iNOS and MMP-9 expression by antagonizing the AP-1, signal transducer, and activator of transcription (STAT) and NF-*κ*B pathways \[[@B11]\]. In a recent paper, it was shown that, similar to that reported for PPAR*α*, PPAR*γ* inhibits NF-*κ*B-driven transcription by physically interacting with both p65 and p50 \[[@B12]\].

The antidiabetic drugs thiazolidinedione (TZDs) are ligands for the *γ* subtype of PPARs. Previous in vitro, in vivo, and uncontrolled human studies have suggested a potential anti-inflammatory effect of PPAR*γ* ligands including TZDs in the colon \[[@B5]\]. Pedersen and Brynskov showed that rosiglitazone (a kind of TZDs) enemas could improve impaired PPAR*γ* activity in inflamed colonic epithelium and have beneficial clinical effect in patients with active ulcerative colitis \[[@B13]\]. In our study, the results showed that the DAI and CMDI of the rosiglitazone treatment group reduced significantly on days 14, 21, and 35 compared to the UC model group, and meanwhile, PPAR*γ* expression increased significantly on days 7, 14, 21, and 35, but the NF-*κ*B and TNF-*α* expression reduced significantly. We verified that rosiglitazone can alleviate the UC symptoms as well as mucosal inflammation and ulceration through improve the colonic mucosal expression of PPAR*γ*.

Furthermore, we used Spearman correlation analysis to study the relationship between PPAR*γ*, NF-*κ*B, and TNF-*α* protein expression in rosiglitazone treatment group. Correlation studies showed that the PPAR*γ* expression was negatively correlated with NF-*κ*B. The NF-*κ*B protein expression was significantly positively correlated with that of TNF-*α*. The result might imply that impaired activity or decreased expression of PPAR*γ* in UC colonic mucosa was deprived of the suppressive capability of NF-*κ*B, which led to the high expression of NF-*κ*B transfer from cytoplasmic form to nuclei and then upregulate the expression of proinflammatory factors such as TNF-*α*.

In conclusion, rosiglitazone can alleviate colonic mucosal inflammatory response and has the protective role on UC by upregulating PPAR*γ* colonic expression and downregulating NF-*κ*B and TNF-*α* expression.
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![Pathological change of control group, UC model group, and rosiglitazone treatment group on day 14 under light microscope (HE×200). The colonic mucosa structure was intact in the control group. Mucosa and submucosa defects could be seen with infiltrations of inflammatory neutrophils and lymphocytes in the lamina propria of the model group on day 14. The degree of mucosal inflammation relieved in the rosiglitazone treatment group on day 14. Regenerated epithelia covered the surface of ulcer and the mucosa tended to be complete. The base of ulcer was filled with tissues and scars.](GRP2012-845672.001){#fig1}

![The colonic mucosal PPAR*γ* protein expression in the control group, UC model group, and rosiglitazone treated group on days 7, 14, 21, 35. In the control group, expression of PPAR*γ* protein in the colonic mucosa was significantly higher compared to the UC model group (*P* \< 0.05). In the rosiglitazone treatment group, PPAR*γ* protein expression increased significantly than that of the model group on days 7, 14, 21, 35 (*P* \< 0.05).](GRP2012-845672.002){#fig2}

![Colonic mucosal NF-*κ*B protein expression in the control group, UC model group, and rosiglitazone treated group on days 7, 14, 21, 35. In the control group, expression of NF-*κ*B protein in the colonic mucosa was significantly less compared to the UC model group (*P* \< 0.05). In the rosiglitazone treatment group, NF-*κ*B protein expression reduced significantly than that of the model group on days 7, 14, 21, and 35 (*P* \< 0.05).](GRP2012-845672.003){#fig3}

![Colonic mucosal TNF-*α* protein expression in the control group, UC model group, and rosiglitazone treated group on days 7, 14, 21, 35. In the control group, expression of TNF-*α* protein in the colonic mucosa was significantly less compared to the UC model group (*P* \< 0.05). In the rosiglitazone treatment group, TNF-*α* protein expression reduced significantly than that of the model group on days 7, 14, 21 and 35 (*P* \< 0.05).](GRP2012-845672.004){#fig4}

###### 

Oligonucleotide of primers of target genes.

  mRNA species   mRNA                                    PCR product                             
  -------------- --------------------------------------- --------------------------------------- --------
  PPAR-*γ*       sense                                   5′-CTT CGG AAT CAG CTC TGT GGA C-3′     352 bp
  antisense      5′-GCA TCC TTC ACA AGC ATG GAC TC-3′                                            
  NF-*κ*Bp65     sense                                   5′-ATG GAC GAT CTGTTT CCC CTC ATC-3′    254 bp
  antisense      5′-ATT GGG TGC GTC TTA GTG GTA TCT-3′                                           
  TNF-*α*        sense                                   5′-CTC CAG CTG GAA GAC TCC TCC CAG-3′   171 bp
  antisense      5′-CCC GAC TAC GTG CTC CTC ACC-3′                                               
  *β*-action     sense                                   5′-AAG CCT AAG GCC AAC CGT GAA AAG-3′   241 bp
  antisense      5′-TCA ATG AGG TAG TCT GTC AGG T-3′                                             

###### 

DAI and CMDI of three groups on different time (mean ± SD).

  Time       Control group   Model group   Rosiglitazone-treatedgroup                                    
  ---------- --------------- ------------- ---------------------------- --------------- ---------------- ----------------
  7th day    0.06 ± 0.14     0.00 ± 0.00   2.89 ± 0.00\*                4.83 ± 0.55\*   2.69 ± 0.25      4.51 ± 0.41
  14th day   0.08 ± 0.14     0.00 ± 0.00   2.41 ± 0.25\*                4.07 ± 0.75\*   1.89 ± 0.35^Δ^   3.42 ± 0.52^Δ^
  21st day   0.00 ± 0.00     0.00 ± 0.00   2.09 ± 0.25\*                3.03 ± 0.52\*   1.53 ± 0.25^Δ^   2.00 ± 0.55^Δ^
  35th day   0.00 ± 0.00     0.00 ± 0.00   1.63 ± 0.46\*                2.33 ± 0.52\*   0.72 ± 0.28^Δ^   1.50 ± 0.55^Δ^

Note: \**P* \< 0.05 versus control group, ^Δ^ *P* \< 0.05 versus model group.

###### 

Colonic mucosal mRNA expression of PPAR*γ*, NF-*κ*B, and TNF-*α* (mean ± SD).

  Time     Control group   Model group   Rosiglitazone-treated group                                                                                       
  -------- --------------- ------------- ----------------------------- --------------- --------------- ----------------- ---------------- ---------------- ----------------
  7th d    1.46 ± 0.05     0.05 ± 0.01   0.03 ± 0.01                   0.61 ± 0.02\*   0.89 ± 0.10\*   1.08 ± 0.1195\*   0.84 ± 0.02^Δ^   0.75 ± 0.08^Δ^   0.83 ± 0.11^Δ^
  14th d   1.46 ± 0.05     0.04 ± 0.00   0.03 ± 0.01                   0.71 ± 0.04\*   0.79 ± 0.05\*   0.88 ± 0.04\*     1.05 ± 0.04^Δ^   0.53 ± 0.05^Δ^   0.72 ± 0.03^Δ^
  21st d   1.45 ± 0.04     0.04 ± 0.00   0.03 ± 0.00                   0.92 ± 0.04\*   0.60 ± 0.05\*   0.73 ± 0.04\*     1.18 ± 0.05^Δ^   0.32 ± 0.03^Δ^   0.52 ± 0.03^Δ^
  35th d   1.47 ± 0.06     0.04 ± 0.01   0.03 ± 0.02                   0.99 ± 0.05\*   0.54 ± 0.03\*   0.52 ± 0.05\*     1.26 ± 0.06^Δ^   0.22 ± 0.03^Δ^   0.22 ± 0.03^Δ^

Note: \**P* \< 0.05 versus control group, ^Δ^ *P* \< 0.05 versus model group.

###### 

Colonic mucosal protein expression of PPAR*γ*, NF-*κ*B, and TNF-*α* (mean ± SD).

  Time     Control group   Model group   Rosiglitazone-treated group                                                                                     
  -------- --------------- ------------- ----------------------------- --------------- --------------- --------------- ---------------- ---------------- ----------------
  7th d    0.04 ± 0.01     0.02 ± 0.01   0.01 ± 0.00                   0.01 ± 0.00\*   0.13 ± 0.01\*   0.10 ± 0.01\*   0.02 ± 0.01^Δ^   0.09 ± 0.01^Δ^   0.08 ± 0.01^Δ^
  14th d   0.04 ± 0.00     0.02 ± 0.00   0.001 ± 0.00                  0.00 ± 0.00\*   0.11 ± 0.01\*   0.07 ± 0.01\*   0.02 ± 0.00^Δ^   0.07 ± 0.01^Δ^   0.05 ± 0.01^Δ^
  21st d   0.04 ± 0.01     0.03 ± 0.00   0.00 ± 0.00                   0.01 ± 0.00\*   0.09 ± 0.01\*   0.06 ± 0.01\*   0.02 ± 0.01^Δ^   0.06 ± 0.01^Δ^   0.02 ± 0.01^Δ^
  35th d   0.04 ± 0.00     0.02 ± 0.01   0.01 ± 0.00                   0.01 ± 0.00\*   0.07 ± 0.01\*   0.05 ± 0.01\*   0.03 ± 0.01^Δ^   0.04 ± 0.00^Δ^   0.02 ± 0.00^Δ^

Note: \**P* \< 0.05 versus control group, ^Δ^ *P* \< 0.05 versus model group.
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